



# Getting back to normal **relies** on **COVID-19** testing

We can help.

Getting your organization back on the road to normalcy means moving forward with confidence and safety. And for most organizations, this “new normal” will rely on testing. But implementing a testing program on your own presents a host of challenges that can seem overwhelming—*that’s where we come in.*

## A one-stop, end-to-end **onsite testing program**

From expert consultation to building and implementing a testing program that works for your organization, we’ll work with our partners to implement a plan that delivers results you can trust—from a company experienced in world-class diagnostic tools and equipment for large-volume testing.

### Simple and **cost effective**

Testing starting at just **\$25 per person\***

An all-inclusive solution:

- Rapid antigen testing using the **BD Veritor™ Plus Analyzer** and test kits
- Flexible program to fit your needs
- Onsite testing and management
- CLIA certification
- Licensed physician order and certified lab director
- Lab required setup/supplies
- Comprehensive results reporting to ensure compliance

\* One invoice for tests, services, IT and distribution. Pricing based on volume and services requested.





## Here's how it works

An all-inclusive solution:



BD consults with you to determine testing needs



BD identifies the right partner to implement your plan



Partner develops testing plan



Partner implements the plan and starts testing (with **BD Veritor™**, nasal swab, rapid antigen testing)



Results are recorded and reported

## Rapid antigen testing—results you can trust

“How much confidence can I have in this result?”

Rapid antigen testing with the **BD Veritor™ Plus System** provides proven and accurate results with **98% overall percent agreement** in just 15 minutes at the point of care.<sup>1</sup>

To find out more about adding COVID-19 testing to your “roadmap to normal,” visit **BDVeritor.com**

\*The intended use of the BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay only includes those who are suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms.

- This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
- This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

#### References:

1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2. Package insert. Becton, Dickinson and Company.

**BDVeritor.com**

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates.  
© 2021 BD. All rights reserved. 821-US-0321 March 2021

